Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2013

01.08.2013 | Epidemiology

Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients

verfasst von: E. J. Bantema-Joppe, E. R. van den Heuvel, L. de Munck, G. H. de Bock, W. G. J. M. Smit, P. R. Timmer, W. V. Dolsma, L. Jansen, C. P. Schröder, S. Siesling, J. A. Langendijk, J. H. Maduro

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

In this study, we tested the hypothesis whether breast conserving therapy (BCT) compared with mastectomy is associated with a negative outcome in terms of distant metastases or death (DMD) and investigated the relation between locoregional recurrence (LRR) and DMD in young breast cancer (BC) patients. This study included a consecutive series of 536 patients ≤40 years of age at diagnosis with pathological T1N0-3M0 BC, treated between 1989 and 2005. A multistate survival model was used to evaluate the influences of local treatment and LRR on DMD, adjusted for potential prognostic factors. Patients were treated with mastectomy (N = 213) or BCT (N = 323). Median age at diagnosis was 36.3 years, with a median follow-up of 9.0 years. The 10-year actuarial cumulative incidence of DMD was 30.6 % after mastectomy and 26.3 % after BCT (P = 0.04). In total, 81 (15 %) LRRs were observed. After BCT, patients had a threefold higher risk of LRR than after mastectomy (HR 2.9; 95 % CI 1.6–5.3). Patients with LRR had a higher risk of DMD compared with patients without LRR (HR 5.5; 95 % CI 2.1–14.5). However, BCT was not negatively associated with DMD-after-LRR (HR 0.47; 95 % CI 0.2–1.1, BCT vs mastectomy). In conclusion, although LRR significantly affected DMD, the increased risk of LRR after BCT compared with mastectomy did not lead to a worse DMD outcome in BC patients ≤40 years of age.
Literatur
1.
Zurück zum Zitat Zhou P, Recht A (2004) Young age and outcome for women with early-stage invasive breast carcinoma. Cancer 101:1264–1274PubMedCrossRef Zhou P, Recht A (2004) Young age and outcome for women with early-stage invasive breast carcinoma. Cancer 101:1264–1274PubMedCrossRef
2.
Zurück zum Zitat Elkhuizen PH, van de Vijver MJ, Hermans J et al (1998) Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 40:859–867PubMedCrossRef Elkhuizen PH, van de Vijver MJ, Hermans J et al (1998) Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 40:859–867PubMedCrossRef
3.
Zurück zum Zitat Huston TL, Simmons RM (2005) Locally recurrent breast cancer after conservation therapy. Am J Surg 189:229–235PubMedCrossRef Huston TL, Simmons RM (2005) Locally recurrent breast cancer after conservation therapy. Am J Surg 189:229–235PubMedCrossRef
4.
Zurück zum Zitat de Bock GH, van der Hage JA, Putter H et al (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42:351–356PubMedCrossRef de Bock GH, van der Hage JA, Putter H et al (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42:351–356PubMedCrossRef
5.
Zurück zum Zitat Jobsen JJ, van der Palen PJ, Meerwaldt JH (2001) The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy. Eur J Cancer 37:1820–1827PubMedCrossRef Jobsen JJ, van der Palen PJ, Meerwaldt JH (2001) The impact of age on local control in women with pT1 breast cancer treated with conservative surgery and radiation therapy. Eur J Cancer 37:1820–1827PubMedCrossRef
6.
Zurück zum Zitat Fredholm H, Eaker S, Frisell J et al (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4:e7695PubMedCrossRef Fredholm H, Eaker S, Frisell J et al (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4:e7695PubMedCrossRef
7.
Zurück zum Zitat van der Leest M, Evers L, van der Sangen MJ et al (2007) The safety of breast-conserving therapy in patients with breast cancer aged ≤40 years. Cancer 109:1957–1964PubMedCrossRef van der Leest M, Evers L, van der Sangen MJ et al (2007) The safety of breast-conserving therapy in patients with breast cancer aged ≤40 years. Cancer 109:1957–1964PubMedCrossRef
8.
Zurück zum Zitat Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19:1688–1697PubMed Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19:1688–1697PubMed
9.
Zurück zum Zitat Zhou P, Gautam S, Recht A (2007) Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 101:51–57PubMedCrossRef Zhou P, Gautam S, Recht A (2007) Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 101:51–57PubMedCrossRef
10.
Zurück zum Zitat van der Sangen MJ, van de Wiel FM, Poortmans PM et al (2010) Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged </=40 years. Breast Cancer Res Treat. 127:207–215PubMedCrossRef van der Sangen MJ, van de Wiel FM, Poortmans PM et al (2010) Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged </=40 years. Breast Cancer Res Treat. 127:207–215PubMedCrossRef
11.
Zurück zum Zitat Kroman N, Holtveg H, Wohlfahrt J et al (2004) Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100:688–693PubMedCrossRef Kroman N, Holtveg H, Wohlfahrt J et al (2004) Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 100:688–693PubMedCrossRef
12.
Zurück zum Zitat de Bock GH, Putter H, Bonnema J et al (2009) The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat 117:401–408PubMedCrossRef de Bock GH, Putter H, Bonnema J et al (2009) The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat 117:401–408PubMedCrossRef
13.
Zurück zum Zitat Vicini FA, Kestin L, Huang R et al (2003) Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 97:910–919PubMedCrossRef Vicini FA, Kestin L, Huang R et al (2003) Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 97:910–919PubMedCrossRef
14.
Zurück zum Zitat Vicini FA, Goldstein NS, Wallace M et al (2008) Molecular evidence demonstrating local treatment failure is the source of distant metastases in some patients treated for breast cancer. Int J Radiat Oncol Biol Phys 71:689–694PubMedCrossRef Vicini FA, Goldstein NS, Wallace M et al (2008) Molecular evidence demonstrating local treatment failure is the source of distant metastases in some patients treated for breast cancer. Int J Radiat Oncol Biol Phys 71:689–694PubMedCrossRef
15.
Zurück zum Zitat Harris EE, Hwang WT, Seyednejad F et al (2003) Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy. Cancer 98:2144–2151PubMedCrossRef Harris EE, Hwang WT, Seyednejad F et al (2003) Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy. Cancer 98:2144–2151PubMedCrossRef
16.
Zurück zum Zitat Anderson SJ, Wapnir I, Dignam JJ et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473PubMedCrossRef Anderson SJ, Wapnir I, Dignam JJ et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473PubMedCrossRef
17.
Zurück zum Zitat Botteri E, Bagnardi V, Rotmensz N et al (2010) Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol 21:723–728PubMedCrossRef Botteri E, Bagnardi V, Rotmensz N et al (2010) Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol 21:723–728PubMedCrossRef
18.
Zurück zum Zitat Visser O, Coebergh JWW, van Dijck JAAM et al (2002) Incidence of cancer in the Netherlands 1998. Netherlands Cancer Registry, Utrecht Visser O, Coebergh JWW, van Dijck JAAM et al (2002) Incidence of cancer in the Netherlands 1998. Netherlands Cancer Registry, Utrecht
19.
Zurück zum Zitat Sobin LH, Wittekind Ch (eds) (2002) TNM classification of malignant tumours, 6th edn. John Wiley & Sons, Hoboken, New Jersey Sobin LH, Wittekind Ch (eds) (2002) TNM classification of malignant tumours, 6th edn. John Wiley & Sons, Hoboken, New Jersey
20.
Zurück zum Zitat Bontenbal M, Nortier JW, Beex LV et al (2000) Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology. Ned Tijdschr Geneeskd 144:984–989PubMed Bontenbal M, Nortier JW, Beex LV et al (2000) Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology. Ned Tijdschr Geneeskd 144:984–989PubMed
21.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef Goldhirsch A, Glick JH, Gelber RD et al (1998) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90:1601–1608PubMedCrossRef
22.
Zurück zum Zitat Putter H, van der Hage J, de Bock GH et al (2006) Estimation and prediction in a multi-state model for breast cancer. Biom J 48:366–380PubMedCrossRef Putter H, van der Hage J, de Bock GH et al (2006) Estimation and prediction in a multi-state model for breast cancer. Biom J 48:366–380PubMedCrossRef
23.
Zurück zum Zitat Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389–2430PubMedCrossRef Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389–2430PubMedCrossRef
24.
Zurück zum Zitat Tanis E, van de Velde CJ, Bartelink H et al (2012) Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer 48:1751–1756PubMedCrossRef Tanis E, van de Velde CJ, Bartelink H et al (2012) Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer 48:1751–1756PubMedCrossRef
25.
Zurück zum Zitat Smith TE, Lee D, Turner BC et al (2000) True recurrence vs new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48:1281–1289PubMedCrossRef Smith TE, Lee D, Turner BC et al (2000) True recurrence vs new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48:1281–1289PubMedCrossRef
26.
Zurück zum Zitat Osborne MP, Borgen PI, Wong GY et al (1992) Salvage mastectomy for local and regional recurrence after breast-conserving operation and radiation therapy. Surg Gynecol Obstet 174:189–194PubMed Osborne MP, Borgen PI, Wong GY et al (1992) Salvage mastectomy for local and regional recurrence after breast-conserving operation and radiation therapy. Surg Gynecol Obstet 174:189–194PubMed
27.
Zurück zum Zitat Janni W, Shabani N, Dimpfl T et al (2001) Matched pair analysis of survival after chest-wall recurrence compared to mammary recurrence: a long-term follow up. J Cancer Res Clin Oncol 127:455–462PubMedCrossRef Janni W, Shabani N, Dimpfl T et al (2001) Matched pair analysis of survival after chest-wall recurrence compared to mammary recurrence: a long-term follow up. J Cancer Res Clin Oncol 127:455–462PubMedCrossRef
28.
Zurück zum Zitat Bantema-Joppe EJ, van der Laan HP, de Bock GH et al (2011) Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: results on local control and survival. Radiother Oncol 100:215–220PubMedCrossRef Bantema-Joppe EJ, van der Laan HP, de Bock GH et al (2011) Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: results on local control and survival. Radiother Oncol 100:215–220PubMedCrossRef
29.
Zurück zum Zitat Poortmans P, Aznar M, Bartelink H (2012) Quality indicators for breast cancer: revisiting historical evidence in the context of technology changes. Semin Radiat Oncol 22:29–39PubMedCrossRef Poortmans P, Aznar M, Bartelink H (2012) Quality indicators for breast cancer: revisiting historical evidence in the context of technology changes. Semin Radiat Oncol 22:29–39PubMedCrossRef
Metadaten
Titel
Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients
verfasst von
E. J. Bantema-Joppe
E. R. van den Heuvel
L. de Munck
G. H. de Bock
W. G. J. M. Smit
P. R. Timmer
W. V. Dolsma
L. Jansen
C. P. Schröder
S. Siesling
J. A. Langendijk
J. H. Maduro
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2650-7

Weitere Artikel der Ausgabe 3/2013

Breast Cancer Research and Treatment 3/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.